HAEM4:Precursor Lymphoid Neoplasms
Revision as of 13:08, 3 November 2023 by Bailey.Glen (talk | contribs) (Created page with "{{Under Construction}} ==Primary Author(s)*== Put your text here __TOC__ ==Graphical Data Links== Put your graphics here ==General Disease Overview / Description of Canc...")
 | This page is under construction |
Primary Author(s)*
Put your text here
Graphical Data Links
Put your graphics here
General Disease Overview / Description of Cancer Category
Put your text here
WHO Classification Pages (Includes Links to Content)
- B-ALL with t(9;22)(q34.1;q11.2); BCR-ABL1 - B-ALL with t(v;11q23.3); KMT2A-Rearranged - B-ALL with t(12;21)(p13.2;q22.1); ETV6-RUNX1 - B-ALL with Hyperdiploidy - B-ALL with Hypodiploidy - B-ALL with t(5;14)(q31.1;q32.1); IGH/IL3 - B-ALL with t(1;19)(q23;p13.3); TCF3-PBX1 - B-ALL, BCR-ABL1-Like - B-ALL with iAMP21 - B-ALL, Not Otherwise Specified
- Early T-Cell Precursor Lymphoblastic Leukemia - NK-Lymphoblastic Leukemia/Lymphoma
Other Related Pages (Includes Links to Content)
- B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
- B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
- B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
- B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
- B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
- B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
- T-ALL/MEF2C
- T-cell lymphoblastic leukemia with t(7;14)(p15;q32)
Additional Information
Put your text here
References
EXAMPLE Book
- Arber DA, et al., (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.
Notes
*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.